Integrating pharmacogenetics, multi‐omics and machine learning in the novel therapeutic view of pulmonary hypertension

It is a complex disease with multiple pathogenesis that causes pulmonary hypertension (PH). In addition to the commonly used drugs for treating PH, pharmacogenomic therapies are facilitating the innovation of personalized medicine to treat PH. Meanwhile, gene therapy has been extensively studied but is a quite challenging task. Furthermore, the gradual widespread application of omics analyses, big data and machine learning is a trend to improve the efficacy of drugs and gene therapy of PH. They are widely used in the screening of drug therapeutic targets and predicting drugs therapeutic effect. The emergence of innovative diagnosis and treatment approaches for PH opens pathways for combining personalized medicine with established pharmacological and gene therapies to achieve effective treatment strategies and further decrease the mortality rate associated with this disease.